XML 18 R29.htm IDEA: XBRL DOCUMENT v2.4.0.6

Summary of Revenue Recognized under Agreement with GSK (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended				1 Months Ended	3 Months Ended		12 Months Ended	3 Months Ended		1 Months Ended	3 Months Ended		12 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013 National Institute Of Allergy And Infectious Diseases	Mar. 31, 2012 National Institute Of Allergy And Infectious Diseases	Sep. 30, 2006 Astra Zeneca	Mar. 31, 2013 Astra Zeneca	Mar. 31, 2012 Astra Zeneca	Dec. 31, 2008 Astra Zeneca	Mar. 31, 2013 National Institutes of Health	Mar. 31, 2012 National Institutes of Health	Dec. 31, 2008 Glaxo, Smith, Kline	Mar. 31, 2013 Glaxo, Smith, Kline	Mar. 31, 2012 Glaxo, Smith, Kline	Dec. 31, 2011 Glaxo, Smith, Kline
Product Information [Line Items]
Initial payment					$ 10,000	$ 180	$ 180				$ 10,000	$ 357	$ 357
Performance of research activities						346	392	4,500						12,000
Total	2,085	2,350				526	572
Grant revenue	$ 760	$ 1,087	$ 598	$ 990					$ 162	$ 97

X

- Definition

Revenue from collaboration agreement.

+ References

No definition available.

+ Details

Name:	dvax_CollaborationRevenue
Namespace Prefix:	dvax_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	us-gaap_ProductInformationLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name:	us-gaap_RevenueFromGrants
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 28

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688



Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration